Joan P. Breyer
Vanderbilt University
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Joan P. Breyer.
Nature Genetics | 2008
Julius Gudmundsson; Patrick Sulem; Thorunn Rafnar; Jon Thor Bergthorsson; Andrei Manolescu; Daniel F. Gudbjartsson; Bjarni A. Agnarsson; Asgeir Sigurdsson; Kristrun R. Benediktsdottir; Thorarinn Blondal; Margret Jakobsdottir; Simon N. Stacey; Jelena Kostic; Kari T. Kristinsson; Birgitta Birgisdottir; Shyamali Ghosh; Droplaug N. Magnusdottir; Steinunn Thorlacius; Gudmar Thorleifsson; S. Lilly Zheng; Jielin Sun; Bao Li Chang; J. Bradford Elmore; Joan P. Breyer; Kate M. McReynolds; Kevin M. Bradley; Brian L. Yaspan; Fredrik Wiklund; Pär Stattin; Sara Lindström
We conducted a genome-wide SNP association study on prostate cancer on over 23,000 Icelanders, followed by a replication study including over 15,500 individuals from Europe and the United States. Two newly identified variants were shown to be associated with prostate cancer: rs5945572 on Xp11.22 and rs721048 on 2p15 (odds ratios (OR) = 1.23 and 1.15; P = 3.9 × 10−13 and 7.7 × 10−9, respectively). The 2p15 variant shows a significantly stronger association with more aggressive, rather than less aggressive, forms of the disease.
Nature Genetics | 2009
Julius Gudmundsson; Patrick Sulem; Daniel F. Gudbjartsson; Thorarinn Blondal; Arnaldur Gylfason; Bjarni A. Agnarsson; Kristrun R. Benediktsdottir; Droplaug N. Magnusdottir; Gudbjorg Orlygsdottir; Margret Jakobsdottir; Simon N. Stacey; Asgeir Sigurdsson; Tiina Wahlfors; Teuvo L.J. Tammela; Joan P. Breyer; Kate M. McReynolds; Kevin M. Bradley; Berta Saez; Javier Godino; Sebastian Navarrete; Fernando Fuertes; Laura Murillo; Eduardo Polo; Katja K. Aben; Inge M. van Oort; Brian K. Suarez; Brian T. Helfand; Donghui Kan; Carlo Zanon; Michael L. Frigge
We report a prostate cancer genome-wide association follow-on study. We discovered four variants associated with susceptibility to prostate cancer in several European populations: rs10934853[A] (OR = 1.12, P = 2.9 × 10−10) on 3q21.3; two moderately correlated (r2 = 0.07) variants, rs16902094[G] (OR = 1.21, P = 6.2 × 10−15) and rs445114[T] (OR = 1.14, P = 4.7 × 10−10), on 8q24.21; and rs8102476[C] (OR = 1.12, P = 1.6 × 10−11) on 19q13.2. We also refined a previous association signal on 11q13 with the SNP rs11228565[A] (OR = 1.23, P = 6.7 × 10−12). In a multivariate analysis using 22 prostate cancer risk variants typed in the Icelandic population, we estimated that carriers in the top 1.3% of the risk distribution are at a 2.5 times greater risk of developing the disease than members of the general population.
G3: Genes, Genomes, Genetics | 2011
Kevin M. Bradley; Joan P. Breyer; David B. Melville; Karl W. Broman; Ela W. Knapik; Jeffrey R. Smith
A surprising diversity of mechanisms controls sex determination of vertebrate organisms, even among closely related species. Both genetic and temperature-dependent systems of sex determination have been described in teleost fish. In the common zebrafish model organism, heteromorphic sex chromosomes are not observed, and the potential role of a genetic component of sex determination remains largely unknown. Here we report a genome-wide linkage study of sex determination in zebrafish using a novel SNP genetic map. We identified loci on zebrafish chromosomes 5 (LOD score 7.9) and 16 (LOD score 9.3) governing sex determination as a complex trait, rather than as an XY or ZW genetic system. Each of these loci contains a prominent candidate gene with a conserved role in sex determination across additional species that suggest potential mechanisms of sex determination in zebrafish. The chromosome 5 locus harbors dmrt1, a key gene in sex determination from fruit flies to humans; mutation of the human DMRT1 ortholog is a cause of complete sex reversal of XY individuals. The chromosome 16 locus harbors cyp21a2; mutation of the human CYP21A2 ortholog is one of the more common causes of pseudohermaphroditism. Mutation detection at each of these candidate genes within the zebrafish cross identified hypomorphic variants on the female-associated allele of each locus. The two loci together accounted for 16% of variance of the trait. Interacting environmental cues are likely to be an additional important component of sex determination in zebrafish.
Breast Cancer Research and Treatment | 2004
Olufemi J. Adegoke; Xiao-Ou Shu; Yu-Tang Gao; Qiuyin Cai; Joan P. Breyer; Jeffrey R. Smith; Wei Zheng
Uridine diphospho-glucuronosyltransferase 1A1 (UGT1A1) is involved in catalyzing estrogen, the hormone that plays a central role in the etiology of breast cancer. A common polymorphism [A(TA)6TAA (allele *1) to A(TA)7TAA change (allele *28)] in the TATA-box of the promoter region of the UGT1A1 gene has been reported to be associated with a reduced transcription of this gene. We investigated the association of this polymorphism with the risk of breast cancer among 1047 breast cancer cases and 1083 community controls in the Shanghai Breast Cancer Study, a population-based case-control study. Approximately same proportion of cases (12.5%) and controls (13.0%) carried the variant allele *28 in the Chinese population (p= 0.32). When stratified by age, carrying the *28 allele was associated with an increased risk of breast cancer among women aged less than 40 years (odds ratio [OR] = 1.7; 95% CI = 1.0–2.7) but not among women 40 years old and over (OR = 0.8; 0.7–1.1). Only a few women were homozygous for the *28 allele, precluding a detailed gene-dose association analysis. Additional analyses showed that, the elevated risk associated with the UGT1A1*28 allele among young women was primarily seen in women who had a later menarche, short menstrual years, absence of family history of breast cancer, low waist-to-hip ratio, or low body-mass index. These results suggested that the *28 allele in the UGT1A1 gene may be associated with an increased risk for breast cancer among Chinese women under age 40. No significant associations were observed with *28 allele and breast cancer risk by estrogen receptor/progesterone receptor status.
Cancer Epidemiology, Biomarkers & Prevention | 2012
Joan P. Breyer; T. Grant Avritt; Kate M. McReynolds; William D. Dupont; Jeffrey R. Smith
Background: A recent study of familial and early onset prostate cancer reported a recurrent rare germline mutation of HOXB13 among men of European descent. The gene resides within the 17q21 hereditary prostate cancer linkage interval. Methods: We evaluated the G84E germline mutation (rs138213197) of HOXB13 in a case–control study of familial prostate cancer at Vanderbilt University (Nashville, TN) to independently evaluate the association of the mutation with familial prostate cancer. We genotyped 928 familial prostate cancer probands and 930 control probands without a personal or family history of prostate cancer. Results: Our study confirmed the association between the G84E mutation of HOXB13 and risk of prostate cancer among subjects of European descent. We observed the mutation in 16 familial cases and in two controls, each as heterozygotes. The odds ratio (OR) for prostate cancer was 7.9 [95% confidence interval, (CI) 1.8–34.5, P = 0.0062] among carriers of the mutation. The carrier rate was 1.9% among all familial case probands and 2.7% among probands of pedigrees with ≥3 affected. In a separate case series of 268 probands of European descent with no additional family history of prostate cancer, the carrier rate was 1.5%. Conclusions: The germline mutation G84E of HOXB13 is a rare but recurrent mutation associated with elevated risk of prostate cancer in men of European descent, with an effect size that is greater than observed for previously validated risk variants of genome wide association studies. Impact: This study independently confirms the association of a germline HOXB13 mutation with familial prostate cancer. Cancer Epidemiol Biomarkers Prev; 21(8); 1348–53. ©2012 AACR.
Genome Biology | 2007
Kevin M. Bradley; J. Bradford Elmore; Joan P. Breyer; Brian L. Yaspan; Jason R. Jessen; Ela W. Knapik; Jeffrey R. Smith
We have identified 645,088 candidate polymorphisms in zebrafish and observe a single nucleotide polymorphism (SNP) validation rate of 71% to 86%, improving with polymorphism confidence score. Variant sites are non-random, with an excess of specific novel T- and A-rich motifs. We positioned half of the polymorphisms on zebrafish genetic and physical maps as a resource for positional cloning. We further demonstrate bulked segregant analysis using the anchored SNPs as a method for high-throughput genetic mapping in zebrafish.
PLOS ONE | 2009
Harold D. Love; S. Erin Booton; Braden Boone; Joan P. Breyer; Tatsuki Koyama; Monica P. Revelo; Scott B. Shappell; Jeffrey R. Smith; Simon W. Hayward
Benign prostatic hyperplasia (BPH) and prostate carcinoma (CaP) are linked to aging and the presence of androgens, suggesting that androgen regulated genes play a major role in these common diseases. Androgen regulation of prostate growth and development depends on the presence of intact epithelial-stromal interactions. Further, the prostatic stroma is implicated in BPH. This suggests that epithelial cell lines are inadequate to identify androgen regulated genes that could contribute to BPH and CaP and which could serve as potential clinical biomarkers. In this study, we used a human prostate xenograft model to define a profile of genes regulated in vivo by androgens, with an emphasis on identifying candidate biomarkers. Benign transition zone (TZ) human prostate tissue from radical prostatectomies was grafted to the sub-renal capsule site of intact or castrated male immunodeficient mice, followed by the removal or addition of androgens, respectively. Microarray analysis of RNA from these tissues was used to identify genes that were; 1) highly expressed in prostate, 2) had significant expression changes in response to androgens, and, 3) encode extracellular proteins. A total of 95 genes meeting these criteria were selected for analysis and validation of expression in patient prostate tissues using quantitative real-time PCR. Expression levels of these genes were measured in pooled RNAs from human prostate tissues with varying severity of BPH pathologic changes and CaP of varying Gleason score. A number of androgen regulated genes were identified. Additionally, a subset of these genes were over-expressed in RNA from clinical BPH tissues, and the levels of many were found to correlate with disease status. Our results demonstrate the feasibility, and some of the problems, of using a mouse xenograft model to characterize the androgen regulated expression profiles of intact human prostate tissues.
Cancer | 2009
William D. Dupont; Joan P. Breyer; Kevin M. Bradley; Peggy A. Schuyler; W. Dale Plummer; Melinda E. Sanders; David L. Page; Jeffrey R. Smith
Protein phosphatase 2A (PP2A) is a major cellular phosphatase and plays key regulatory roles in growth, differentiation, and apoptosis. Women who are diagnosed with benign proliferative breast disease are at increased risk for the subsequent development of breast cancer.
Cancer Epidemiology, Biomarkers & Prevention | 2008
Chuanzhong Ye; Yu-Tang Gao; Wanqing Wen; Joan P. Breyer; Xiao-Ou Shu; Jeffrey R. Smith; Wei Zheng; Qiuyin Cai
Mitochondrial genome alternations may be involved in carcinogenesis. The noncoding region of the mitochondrial DNA (mtDNA) displacement loop (D-loop) has emerged as a mutational hotspot. Using data from a population-based case-control study conducted among Chinese women in Shanghai, we evaluated associations of breast cancer risk and survival with the mtDNA D-loop (CA)n dinucleotide repeat polymorphism. Included in the study were 1,058 cases and 1,129 age frequency–matched community controls that participated in the Shanghai Breast Cancer Study between 1996 and 1998. Breast cancer patients were followed to determine intervals of overall survival and disease-free survival. Overall, there was no association between the mtDNA D-loop (CA)n repeat polymorphism and breast cancer risk. Patients with multiple alleles of the mtDNA D-loop (CA)n polymorphism (heteroplasmy) had significantly poorer disease-free survival than those with one allele of the mtDNA D-loop (CA)n polymorphism (hazard ratio 1.62; 95% confidence interval, 1.16-2.26). These results suggest that the mtDNA D-loop (CA)n repeat polymorphism may be associated with breast cancer survival. Additional studies with a larger sample size are warranted. (Cancer Epidemiol Biomarkers Prev 2008;17(8):2117–22)
Cancer Epidemiology, Biomarkers & Prevention | 2009
Joan P. Breyer; Kate M. McReynolds; Brian L. Yaspan; Kevin M. Bradley; William D. Dupont; Jeffrey R. Smith
The genetic variants underlying the strong heritable component of prostate cancer remain largely unknown. Genome-wide association studies of prostate cancer have yielded several variants that have significantly replicated across studies, predominantly in cases unselected for family history of prostate cancer. Additional candidate gene variants have also been proposed, many evaluated within familial prostate cancer study populations. Such variants hold great potential value for risk stratification, particularly for early-onset or aggressive prostate cancer, given the comorbidities associated with current therapies. Here, we investigate a Caucasian study population of 523 independent familial prostate cancer cases and 523 age-matched controls without a personal or family history of prostate cancer. We replicate identified associations at genome-wide association study loci 8q24, 11q13, and 2p15 (P = 2.9 × 10−4 to P = 4.7 × 10−5), showing study population power. We also find evidence to support reported associations at candidate genes RNASEL, EZH2, and NKX3-1 (P = 0.031 to P = 0.0085). We further explore a set of candidate genes related to RNASEL and to its role in retroviral restriction, identifying nominal associations at XPR1 and RBM9. The effects at 8q24 seem more pronounced for those diagnosed at an early age, whereas at 2p15 and RNASEL the effects were more pronounced at a later age. However, these trends did not reach statistical significance. The effects at 2p15 were statistically significantly more pronounced for those diagnosed with aggressive disease. (Cancer Epidemiol Biomarkers Prev 2009;18(7):2137–44)